KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Research & Development (2018 - 2025)

Esperion Therapeutics' Research & Development history spans 8 years, with the latest figure at $13.9 million for Q4 2025.

  • For Q4 2025, Research & Development rose 26.87% year-over-year to $13.9 million; the TTM value through Dec 2025 reached $47.9 million, up 3.49%, while the annual FY2025 figure was $47.9 million, 3.49% up from the prior year.
  • Research & Development reached $13.9 million in Q4 2025 per ESPR's latest filing, down from $14.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $33.0 million in Q4 2022 to a low of $7.2 million in Q2 2025.
  • Average Research & Development over 5 years is $20.3 million, with a median of $19.9 million recorded in 2023.
  • Peak YoY movement for Research & Development: crashed 57.29% in 2024, then skyrocketed 35.91% in 2025.
  • A 5-year view of Research & Development shows it stood at $27.6 million in 2021, then rose by 19.62% to $33.0 million in 2022, then crashed by 46.29% to $17.7 million in 2023, then plummeted by 38.13% to $11.0 million in 2024, then increased by 26.87% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Research & Development are $13.9 million (Q4 2025), $14.1 million (Q3 2025), and $7.2 million (Q2 2025).